CD8A and neoplasm: It can be speculated that immunotherapies that block the pathways that suppress tumour immune responses for patients with LUAD in the high‐index group may increase the presentation of cancer‐associated antigens, resulting in the recovery of the immune response of CD8+ T cells,47 which may then result in better immunotherapy effects.